ID

41174

Descrizione

The BEACON Study (Breast Cancer Outcomes With NKTR-102); ODM derived from: https://clinicaltrials.gov/show/NCT01492101

collegamento

https://clinicaltrials.gov/show/NCT01492101

Keywords

versioni (1)
  1. 05/07/20 05/07/20 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

5 luglio 2020

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Locally Recurrent Breast Cancer NCT01492101

Inglese

Eligibility Locally Recurrent Breast Cancer NCT01492101

1 moduli  
Criteria
Descrizione

Criteria

patient is an adult female with histologically or cytologically confirmed carcinoma of the breast for whom single-agent cytotoxic chemotherapy is indicated
Descrizione

Adult | Gender | Breast Carcinoma | Indication Cytotoxic Chemotherapy Single Agent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0079399
UMLS CUI [3]
C0678222
UMLS CUI [4,1]
C3146298
UMLS CUI [4,2]
C0677881
UMLS CUI [4,3]
C4763675
patient can have either measurable or non-measurable disease by recist.
Descrizione

Measurable Disease | Disease Non-Measurable

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C1518373
patient has received prior therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) with an anthracycline, a taxane and capecitabine
Descrizione

Prior Therapy Neoadjuvant | Prior Therapy Adjuvant | Prior Therapy Neoplasm Metastasis | Anthracyclines | taxane | capecitabine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0600558
UMLS CUI [2,1]
C1514463
UMLS CUI [2,2]
C1522673
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C0027627
UMLS CUI [4]
C0282564
UMLS CUI [5]
C0215136
UMLS CUI [6]
C0671970
patient has minimum of 2 and a maximum of 5 prior cytotoxic chemotherapy regimens with the last dose administered within 6 months. a minimum of two chemotherapy regimens had to be for locally recurrent and/or metastatic disease. all therapy received prior to a diagnosis of metastatic disease (eg, neoadjuvant, adjuvant or repeated adjuvant therapy following a second resection) is counted as one regimen.
Descrizione

Cytotoxic Chemotherapy Quantity Locally Recurrent Malignant Neoplasm | Cytotoxic Chemotherapy Quantity Neoplasm Metastasis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C2986682
UMLS CUI [2,1]
C0677881
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0027627
patient has eastern cooperative oncology group (ecog) performance status of 0 or 1.
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
adequate hematopoietic, liver and kidney functions.
Descrizione

Function Hematopoietic | Liver function | Renal function

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0031843
UMLS CUI [1,2]
C0229601
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
exclusion criteria (major highlights):
Descrizione

Exclusion Criteria Main

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
patient with chemotherapy within 21 days, radiotherapy within 14 days, biological therapy with 14 days, hormonal therapy within 7 days and investigational therapy within 21 days prior to randomization.
Descrizione

Chemotherapy | Therapeutic radiology procedure | Biological treatment | Hormone Therapy | Therapy, Investigational

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1522449
UMLS CUI [3]
C1531518
UMLS CUI [4]
C0279025
UMLS CUI [5]
C0949266
patient with any major surgery within 28 days prior to randomization.
Descrizione

Major surgery

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0679637
patient with concurrent use of biologic agents for the treatment of cancer including antibodies or any investigational agent(s).
Descrizione

Biological agents Cancer treatment | Antibodies | Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0005515
UMLS CUI [1,2]
C0920425
UMLS CUI [2]
C0003241
UMLS CUI [3]
C0013230
patient with prior treatment for cancer with a camptothecin derivative.
Descrizione

Cancer treatment Previous | Camptothecin Derivative

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C0006812
UMLS CUI [2,2]
C1527240
patient with chronic or acute gi disorders resulting in diarrhea of any severity grade; patients who are using chronic anti-diarrheal supportive care to control diarrhea in the 28 days prior to randomization.
Descrizione

Gastrointestinal Diseases chronic | Gastrointestinal Diseases | Diarrhea CTCAE Grades | Antidiarrheal supportive care chronic

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0017178
UMLS CUI [1,2]
C0205191
UMLS CUI [2]
C0017178
UMLS CUI [3,1]
C0011991
UMLS CUI [3,2]
C1516728
UMLS CUI [4,1]
C0853588
UMLS CUI [4,2]
C0205191
patient received pharmacotherapy for hepatitis b or c, tuberculosis or hiv.
Descrizione

Pharmacotherapy Hepatitis B | Pharmacotherapy Hepatitis C | Pharmacotherapy Tuberculosis | Pharmacotherapy HIV Infection

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013216
UMLS CUI [1,2]
C0019163
UMLS CUI [2,1]
C0013216
UMLS CUI [2,2]
C0019196
UMLS CUI [3,1]
C0013216
UMLS CUI [3,2]
C0041296
UMLS CUI [4,1]
C0013216
UMLS CUI [4,2]
C0019693
patient with known cirrhosis diagnosed with child-pugh class a or higher liver disease.
Descrizione

Liver Cirrhosis | Liver disease Child-Pugh Clinical Classification

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023890
UMLS CUI [2,1]
C0023895
UMLS CUI [2,2]
C4050412
patient with prior malignancy (other than breast cancer) except for non-melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 5 years prior to randomization.
Descrizione

Malignant Neoplasm | Exception Breast Carcinoma | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of bladder | Exception Definitive Treatment Previous

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0678222
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0699893
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0851140
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0154091
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C2986592
UMLS CUI [6,3]
C0205156
patient requiring daily use of oxygen supplementation in the 28 days prior to randomization.
Descrizione

Patient need for Oxygen supplementation Daily

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0686904
UMLS CUI [1,2]
C0919655
UMLS CUI [1,3]
C0332173
patients with significant cardiovascular impairment.
Descrizione

Cardiovascular impairment

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0848757
Ritorna all'inizio della pagina

Similar models

Eligibility Locally Recurrent Breast Cancer NCT01492101

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Adult | Gender | Breast Carcinoma | Indication Cytotoxic Chemotherapy Single Agent
Item
patient is an adult female with histologically or cytologically confirmed carcinoma of the breast for whom single-agent cytotoxic chemotherapy is indicated
boolean
C0001675 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0678222 (UMLS CUI [3])
C3146298 (UMLS CUI [4,1])
C0677881 (UMLS CUI [4,2])
C4763675 (UMLS CUI [4,3])
Measurable Disease | Disease Non-Measurable
Item
patient can have either measurable or non-measurable disease by recist.
boolean
C1513041 (UMLS CUI [1])
C0012634 (UMLS CUI [2,1])
C1518373 (UMLS CUI [2,2])
Prior Therapy Neoadjuvant | Prior Therapy Adjuvant | Prior Therapy Neoplasm Metastasis | Anthracyclines | taxane | capecitabine
Item
patient has received prior therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) with an anthracycline, a taxane and capecitabine
boolean
C1514463 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C1522673 (UMLS CUI [2,2])
C1514463 (UMLS CUI [3,1])
C0027627 (UMLS CUI [3,2])
C0282564 (UMLS CUI [4])
C0215136 (UMLS CUI [5])
C0671970 (UMLS CUI [6])
Cytotoxic Chemotherapy Quantity Locally Recurrent Malignant Neoplasm | Cytotoxic Chemotherapy Quantity Neoplasm Metastasis
Item
patient has minimum of 2 and a maximum of 5 prior cytotoxic chemotherapy regimens with the last dose administered within 6 months. a minimum of two chemotherapy regimens had to be for locally recurrent and/or metastatic disease. all therapy received prior to a diagnosis of metastatic disease (eg, neoadjuvant, adjuvant or repeated adjuvant therapy following a second resection) is counted as one regimen.
boolean
C0677881 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C2986682 (UMLS CUI [1,3])
C0677881 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0027627 (UMLS CUI [2,3])
ECOG performance status
Item
patient has eastern cooperative oncology group (ecog) performance status of 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Function Hematopoietic | Liver function | Renal function
Item
adequate hematopoietic, liver and kidney functions.
boolean
C0031843 (UMLS CUI [1,1])
C0229601 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Exclusion Criteria Main
Item
exclusion criteria (major highlights):
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Chemotherapy | Therapeutic radiology procedure | Biological treatment | Hormone Therapy | Therapy, Investigational
Item
patient with chemotherapy within 21 days, radiotherapy within 14 days, biological therapy with 14 days, hormonal therapy within 7 days and investigational therapy within 21 days prior to randomization.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C1531518 (UMLS CUI [3])
C0279025 (UMLS CUI [4])
C0949266 (UMLS CUI [5])
Major surgery
Item
patient with any major surgery within 28 days prior to randomization.
boolean
C0679637 (UMLS CUI [1])
Biological agents Cancer treatment | Antibodies | Investigational New Drugs
Item
patient with concurrent use of biologic agents for the treatment of cancer including antibodies or any investigational agent(s).
boolean
C0005515 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
C0003241 (UMLS CUI [2])
C0013230 (UMLS CUI [3])
Cancer treatment Previous | Camptothecin Derivative
Item
patient with prior treatment for cancer with a camptothecin derivative.
boolean
C0920425 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0006812 (UMLS CUI [2,1])
C1527240 (UMLS CUI [2,2])
Gastrointestinal Diseases chronic | Gastrointestinal Diseases | Diarrhea CTCAE Grades | Antidiarrheal supportive care chronic
Item
patient with chronic or acute gi disorders resulting in diarrhea of any severity grade; patients who are using chronic anti-diarrheal supportive care to control diarrhea in the 28 days prior to randomization.
boolean
C0017178 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0017178 (UMLS CUI [2])
C0011991 (UMLS CUI [3,1])
C1516728 (UMLS CUI [3,2])
C0853588 (UMLS CUI [4,1])
C0205191 (UMLS CUI [4,2])
Pharmacotherapy Hepatitis B | Pharmacotherapy Hepatitis C | Pharmacotherapy Tuberculosis | Pharmacotherapy HIV Infection
Item
patient received pharmacotherapy for hepatitis b or c, tuberculosis or hiv.
boolean
C0013216 (UMLS CUI [1,1])
C0019163 (UMLS CUI [1,2])
C0013216 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
C0013216 (UMLS CUI [3,1])
C0041296 (UMLS CUI [3,2])
C0013216 (UMLS CUI [4,1])
C0019693 (UMLS CUI [4,2])
Liver Cirrhosis | Liver disease Child-Pugh Clinical Classification
Item
patient with known cirrhosis diagnosed with child-pugh class a or higher liver disease.
boolean
C0023890 (UMLS CUI [1])
C0023895 (UMLS CUI [2,1])
C4050412 (UMLS CUI [2,2])
Malignant Neoplasm | Exception Breast Carcinoma | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of bladder | Exception Definitive Treatment Previous
Item
patient with prior malignancy (other than breast cancer) except for non-melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 5 years prior to randomization.
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0154091 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C2986592 (UMLS CUI [6,2])
C0205156 (UMLS CUI [6,3])
Patient need for Oxygen supplementation Daily
Item
patient requiring daily use of oxygen supplementation in the 28 days prior to randomization.
boolean
C0686904 (UMLS CUI [1,1])
C0919655 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])
Cardiovascular impairment
Item
patients with significant cardiovascular impairment.
boolean
C0848757 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial